D. Lane

发表

A. Levine, B. Vogelstein, D. Lane, 2000, Nature.

J. Levine, A. Levine, B. Vogelstein, 2000, Nature.

Reactivation of mutant p 53 : constraints on mechanism highlighted by principal component analysis of the DNA binding domain

J. Essex, D. Lane, C. Verma, 2016 .

Reactivation of mutant p53: Constraints on mechanism highlighted by principal component analysis of the DNA binding domain

J. Essex, D. Lane, C. Verma, 2016, Proteins.

Dimerization of the core domain of the p53 family: A computational study

D. Lane, C. Verma, A. Madhumalar, 2009, Cell cycle.

Simulations of mutant p53 DNA binding domains reveal a novel druggable pocket

Mohan R. Pradhan, C. Kwoh, D. Lane, 2019, Nucleic acids research.

R248Q mutation—Beyond p53‐DNA binding

Adelene Y. L. Sim, D. Lane, C. Verma, 2015, Proteins: Structure, Function, and Bioinformatics.

Mapping the Structural and Dynamical Features of Multiple p53 DNA Binding Domains: Insights into Loop 1 Intrinsic Dynamics

Suryani Lukman, David P. Lane, Chandra S. Verma, 2013, PloS one.

The Mdm2 and p53 genes are conserved in the Arachnids

D. Lane, C. Verma, A. Madhumalar, 2010, Cell cycle.

p53 isoforms can regulate p53 transcriptional activity.

David P Lane, D. Lane, M. Saville, 2005, Genes & development.

Understanding p53 functions through p53 antibodies

D. Lane, K. Sabapathy, 2019, Journal of molecular cell biology.

Transcription Factors as Detection and Diagnostic Biomarkers in Cancer

D. Lane, F. Ghadessy, W. Goh, 2017 .

The p53–Mdm2 interaction and the E3 ligase activity of Mdm2/Mdm4 are conserved from lampreys to humans

S. Brenner, B. Venkatesh, B. Tay, 2016, Genes & development.

Drugging the p53 pathway: understanding the route to clinical efficacy

D. Lane, K. Khoo, C. Verma, 2014, Nature Reviews Drug Discovery.

Strategies for manipulating the p53 pathway in the treatment of human cancer

Ted R. Hupp, David P. Lane, D. Lane, 2000 .

Biochemical characterization of different conformational states of the Sf9 cell‐purified p53His175 mutant protein

D. Lane, T. Hupp, P. Cohen, 1999, FEBS letters.

The N terminus of the murine p53 tumour suppressor is an independent regulatory domain affecting activation and thermostability.

D. Lane, S. Hansen, C. Midgley, 1998, Journal of molecular biology.

Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability.

A. Fersht, D. Lane, P. Nikolova, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Thermodynamic stability of wild-type and mutant p53 core domain.

A. Fersht, B. DeDecker, M. Proctor, 1997, Proceedings of the National Academy of Sciences of the United States of America.

The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target.

D. Lane, D. Barnes, S. Picksley, 1996, Acta oncologica.

Allosteric Regulation of the Thermostability and DNA Binding Activity of Human p53 by Specific Interacting Proteins (*)

D. Lane, S. Hansen, T. Hupp, 1996, The Journal of Biological Chemistry.

Tumour suppressors, kinases and clamps: How p53 regulates the cell cycle in response to DNA damage

D. Lane, L. Cox, 1995, BioEssays : news and reviews in molecular, cellular and developmental biology.

The dominating effect of mutant p53

D. Lane, B. C. Hann, Byron C. Hann, 1995, Nature Genetics.

Two Distinct Signaling Pathways Activate the Latent DNA Binding Function of p53 in a Casein Kinase II-independent Manner (*)

D. Lane, T. Hupp, D. Lane, 1995, Journal of Biological Chemistry.

On the regulation of the p53 tumour suppressor, and its role in the cellular response to DNA damage.

D. Lane, B. Vojtesek, T. Hupp, 1995, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

p53 and Rb: their cellular roles.

D. Lane, S. Picksley, 1994, Current opinion in cell biology.

Mutant conformation of p53. Precise epitope mapping using a filamentous phage epitope library.

D. Lane, C. Stephen, C W Stephen, 1992, Journal of molecular biology.

Rapid colorimetric detection of p53 protein function using DNA-gold nanoconjugates with applications for drug discovery and cancer diagnostics.

Farid Ghadessy, Jun Li, David Lane, 2018, Colloids and surfaces. B, Biointerfaces.

How p 53 wields the scales of fate Arrest or death ?

D. Lane, A. Goh, 2012 .

How p53 wields the scales of fate

D. Lane, A. Goh, 2012, Transcription.

Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome

David F. Callen, David P. Lane, D. Lane, 2011, Oncotarget.

p53 Research: the past thirty years and the next thirty years.

David Lane, A. Levine, D. Lane, 2010, Cold Spring Harbor perspectives in biology.

What the papers say: The p53‐mdm2 autoregulatory feedback loop: A paradigm for the regulation of growth control by p53?

D. Lane, S. Picksley, S M Picksley, 1993 .

Differential induction of transcriptionally active p53 following UV or lonizing radiation: Defects in chromosome instability syndromes?

Xin Lu, David P. Lane, D. Lane, 1993, Cell.

Mdm2-Mediated NEDD8 Conjugation of p53 Inhibits Its Transcriptional Activity

D. Lane, M. Saville, J. Bourdon, 2004, Cell.

Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53.

D. Lane, D. Xirodimas, C. Stephen, 2001, Experimental cell research.

Inhibition of Nutlin-Resistant HDM2 Mutants by Stapled Peptides

D. Lane, C. Verma, F. Ghadessy, 2013, PloS one.

Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents.

Peter M Fischer, Wayne Jackson, Campbell McInnes, 2010, Chemistry & biology.

The p53 knowledgebase: an integrated information resource for p53 research

D. Lane, B. Vojtesek, D. Coomber, 2007, Oncogene.

P53 in cancer: a paradigm for modern management of cancer.

D. Lane, R. Steele, R. Steele, 2005, The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland.

On the expression of the p53 protein in human cancer

D. Lane, 2004, Molecular Biology Reports.

The p53 tumour suppressor gene

D. Lane, R. Steele, P. Hall, 1998, The British journal of surgery.

Oxidative stress is involved in the UV activation of p53.

D. Lane, S. Hansen, J. Renzing, 1996, Journal of cell science.

The Immunocytochemical Detection of P53 Protein In Cytological Specimens: Technical Considerations

D. Lane, P. Hall, S. Dowell, 1994, Cytopathology : official journal of the British Society for Clinical Cytology.

The role of the p53 protein in the apoptotic response.

D. Lane, T. Hupp, P. Hall, 1994, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

Expression of P53 protein in normal, dysplastic, and malignant gastric mucosa: An immunohistochemical study

A. Cuschieri, D. Lane, B. Joypaul, 1993, The Journal of pathology.

ras-Induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation

D. Lane, T. Thompson, Xin Lu, 1992, Cell.

p53, guardian of the genome

D. Lane, D. P. Lane, D. Lane, 1992, Nature.

Checkpoint policing by p53

D. Lane, 1992, Nature.

Wetting of nonconserved residue‐backbones: A feature indicative of aggregation associated regions of proteins

Mohan R. Pradhan, D. Lane, C. Verma, 2016, Proteins.

Differences in the transactivation domains of p53 family members: a computational study

Chandra Verma, David P Lane, Arumugam Madhumalar, 2010, BMC Genomics.

Awakening guardian angels: drugging the p53 pathway

Alan R. Fersht, Christopher J. Brown, Sonia Lain, 2009, Nature Reviews Cancer.

Strategies for manipulating the p53 pathway in the treatment of human cancer.

D. Lane, T. Hupp, K. Ball, 2000, The Biochemical journal.

Molecular characterization of the hdm2-p53 interaction.

S F Howard, D. Lane, C. García-echeverría, 1997, Journal of molecular biology.

Modification of Two Distinct COOH-terminal Domains Is Required for Murine p53 Activation by Bacterial Hsp70*

R. Morimoto, D. Lane, S. Hansen, 1996, The Journal of Biological Chemistry.

p53: oncogene or anti-oncogene?

D. Lane, S. Benchimol, D P Lane, 1990, Genes & development.

Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli.

J. Bartek, D. Lane, B. Vojtesek, 1992, Journal of cell science.

Long range recognition and selection in IDPs: the interactions of the C-terminus of p53

Srinivasaraghavan Kannan, David P. Lane, Chandra S. Verma, 2016, Scientific Reports.

p53 isoform Δ113p53/Δ133p53 promotes DNA double-strand break repair to protect cell from death and senescence in response to DNA damage

Zhenhai Zhang, D. Lane, Zhao Ou, 2015, Cell Research.

Differential binding of p53 and nutlin to MDM2 and MDMX: Computational studies

Chandra S Verma, Christopher J Brown, David P Lane, 2010, Cell cycle.

Stapled peptides in the p53 pathway: Computer simulations reveal novel interactions of the staples with the target protein

D. Lane, C. Verma, T. Joseph, 2010, Cell cycle.

Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9

T. Lim, H. Gabra, D. Lane, 2013, Cell cycle.

p53 in health and disease

Karen H. Vousden, David P. Lane, D. Lane, 2007, Nature Reviews Molecular Cell Biology.

The characterisation of p53 binding phage isolated from phage peptide display libraries.

D. Lane, D. Daniels, 1994, Journal of molecular biology.

Diversity of human p53 mutants revealed by complex formation to SV40 T antigen.

J. Bartek, D. Lane, B. Vojtesek, 1992, European journal of cancer.

Cellular proteins involved in SV40 transformation

D. Lane, J. Gannon, 1983 .

The RNA helicase p68 (DDX5) is selectively required for the induction of p53-dependent p21 expression and cell cycle arrest after DNA damage

F. Fuller-Pace, D. Lane, S. Nicol, 2012, Oncogene.

Nucleophosmin interacts with HEXIM1 and regulates RNA polymerase II transcription.

T. Lim, D. Lane, Jialing Lee, 2008, Journal of molecular biology.

Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A.

R. Fåhraeus, D. Lane, K. Ball, 1996, Current Biology.

Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide from p16CDKN2/INK4A

R. Fåhraeus, D. Lane, K. Ball, 1996, Current Biology.

Seliciclib (CYC202, R‐roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model

A. Thompson, D. Lane, S. Bray, 2009, International journal of cancer.

In vitro and In vivo Pharmacokinetic-Pharmacodynamic Relationships for the Trisubstituted Aminopurine Cyclin-Dependent Kinase Inhibitors Olomoucine , Bohemine and CYC 202

S. Clarke, D. Lane, S. Whittaker, 2005 .

In vitro and In vivo Pharmacokinetic-Pharmacodynamic Relationships for the Trisubstituted Aminopurine Cyclin-Dependent Kinase Inhibitors Olomoucine, Bohemine and CYC202

S. Clarke, D. Lane, P. Workman, 2005, Clinical Cancer Research.

Rapid induction of apoptosis mediated by peptides that bind initiation factor eIF4E

R. Fåhraeus, A. Prescott, D. Lane, 2000, Current Biology.

International network of cancer genome projects

Gary D Bader, Benjamin J. Raphael, Joshua M. Stuart, 2010, Nature.

Transcription — guarding the genome by sensing DNA damage

D. Lane, M. Ljungman, 2004, Nature Reviews Cancer.

Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop.

Su-Ying Wu, P. Taylor, D. Lane, 2003, Structure.

p53 mutations in colorectal cancer.

W. Bodmer, A. Rowan, D. Lane, 1990, Proceedings of the National Academy of Sciences of the United States of America.

p53 protein in odontogenic cysts: increased expression in some odontogenic keratocysts.

D. Lane, G. Ogden, D. Chisholm, 1992, Journal of clinical pathology.

Assessment of p53 protein expression in normal, benign, and malignant oral mucosa

D. Lane, G. Ogden, D. Lunny, 1992, The Journal of pathology.

p53 Immunohistochemistry in malignant fibrous histiocytomas and other mesenchymal tumours

D. Lane, Y. Soini, P. Pääkkö, 1992, The Journal of pathology.

Structure-activity relationship of truncated and substituted analogues of the intracellular delivery vector Penetratin.

R. Fåhraeus, D. Lane, P. Fischer, 2000, The journal of peptide research : official journal of the American Peptide Society.

Interaction of kendomycin and semi-synthetic analogues with the anti-apoptotic protein Bcl-xl.

A. D. Buss, D. Lane, K. Wan, 2008, Bioorganic & medicinal chemistry letters.

Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design.

Su-Ying Wu, P. Taylor, D. Lane, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics.

D. Lane, P. Fischer, D P Lane, 2000, Current medicinal chemistry.

Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides.

D. Lane, B. Vojtesek, S. Picksley, 1994, Oncogene.

Phosphatase WIP1 regulates adult neurogenesis and WNT signaling during aging.

D. Lane, Yunhua Zhu, O. Demidov, 2014, The Journal of clinical investigation.

Structure and function of SV40 large-T antigen.

D. Lane, J. Gannon, S. Mole, 1987, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols.

M. Fernö, Å. Borg, D. Lane, 1995, British Journal of Cancer.

Human and plant proliferating-cell nuclear antigen have a highly conserved binding site for the p53-inducible gene product p21WAF1.

D. Lane, K. Ball, D. Lane, 1996, European journal of biochemistry.

The p16INK4a tumour suppressor protein inhibits αvβ3 integrin‐mediated cell spreading on vitronectin by blocking PKC‐dependent localization of αvβ3 to focal contacts

R. Fåhraeus, D. Lane, D. Lane, 1999 .

Characterization, chemical optimization and anti-tumor activity of a tubulin poison identified by a p53-based phenotypic screen

A. Slawin, A. Thompson, D. Lane, 2008, Cell cycle.

Characterization of a new intrabody directed against the N-terminal region of human p53

D. Lane, P. Cohen, J. Mani, 1998, Oncogene.

Translating p53 into the clinic

David P. Lane, Chandra S. Verma, J. Baselga, 2010, Nature Reviews Clinical Oncology.

Negative regulation of viral enhancers in undifferentiated embryonic stem cells

P. Rigby, D. Lane, C. Gorman, 1985, Cell.

Effect of VH–VL Families in Pertuzumab and Trastuzumab Recombinant Production, Her2 and FcγIIA Binding

D. Lane, J. Yeo, S. Gan, 2018, Front. Immunol..

The effects of Antibody Engineering CH and CL in Trastuzumab and Pertuzumab recombinant models: Impact on antibody production and antigen-binding

D. Lane, J. Yeo, S. Gan, 2018, Scientific Reports.

WP 1 : Cell Biology , Autopoiesis and Biological Design Patterns D 1 . 4 : Mathematical Models of Gene Expression Computing

Chrystopher L. Nehaniv, M. Schilstra, A. Thompson, 2022 .

P14ARF promotes accumulation of SUMO‐1 conjugated (H)Mdm2

D. Lane, D. Xirodimas, R. Hay, 2002, FEBS letters.

Oligomerization of the Human ARF Tumor Suppressor and Its Response to Oxidative Stress*

D. Lane, D. Coomber, S. Laín, 2003, Journal of Biological Chemistry.

p14 Arf Promotes Small Ubiquitin-like Modifier Conjugation of Werners Helicase*

A. Prescott, D. Lane, M. Saville, 2004, Journal of Biological Chemistry.

Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse.

D. Lane, P. Workman, P. Fischer, 2005, Molecular cancer therapeutics.

Defective nuclear localization of p53 protein in a Chinese hamster cell line is associated with the formation of stable cytoplasmic protein multimers in cells with gene amplification.

D. Lane, G. Fronza, P. Campomenosi, 2000, Carcinogenesis.

Gating by tryptophan 73 exposes a cryptic pocket at the protein-binding interface of the oncogenic eIF4E protein.

D. Lane, C. Verma, Dilraj Lama, 2015, Biochemistry.

Loss of heterozygosity and mutational alterations of the p53 gene in skin tumours of interspecific hybrid mice.

A. Balmain, D. Lane, P. Burns, 1991, Oncogene.

Killing tumor cells with viruses—a question of specificity

D. Lane, 1998, Nature Network Boston.

Macrocyclization of an all-d linear α-helical peptide imparts cellular permeability† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c9sc06383h

D. Lane, L. Rénia, Y. S. Tan, 2020, Chemical science.

Macrocyclization of an all-D linear peptide improves target affinity and imparts cellular activity: A novel stapled α-helical peptide modality

D. Lane, Y. S. Tan, C. Verma, 2019, bioRxiv.

Recognition Dynamics of p53 and MDM2: Implications for Peptide Design.

D. Lane, L. Caves, C. Verma, 2016, The journal of physical chemistry. B.

Ubiquitination of HEXIM1 by HDM2

Qiao Jing Lew, D. Lane, O. Bensaude, 2009, Cell cycle.

The p53 isoform, Δ133p53α, stimulates angiogenesis and tumour progression

D. Lane, J. Bourdon, A. Prats, 2013, Oncogene.

p53 directly transactivates Δ133p53α, regulating cell fate outcome in response to DNA damage

D. Lane, J. Bourdon, K. Fernandes, 2011, Cell Death and Differentiation.

Constitutive activation of WASp leads to abnormal cytotoxic cells with increased granzyme B and degranulation response to target cells

J. Orange, Minghui He, S. Snapper, 2021, JCI Insight.

Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners

R. Metcalf, J. Samet, C. Harris, 1992, The Lancet.

p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate.

D. Neal, D. Lane, M. Robinson, 1992, The Journal of urology.

Inflammation-associated genomic instability in cancer

D. Lane, V. Tergaonkar, K. H. Pua, 2019, Genome Instability & Disease.

Anatomy of Mdm2 and Mdm4 in evolution

D. Lane, Y. S. Tan, F. Ghadessy, 2017, Journal of molecular cell biology.

Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro

J. Bartek, J. Bártková, J. Kovarik, 1990, International journal of cancer.

Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumours.

J. Bartek, J. Lukas, J. Bártková, 1993, European journal of cancer.

Autophagic degradation of the inhibitory p53 isoform Δ133p53α as a regulatory mechanism for p53-mediated senescence

C. Harris, E. Appella, D. Lane, 2014, Nature Communications.

Positive feedback between p53 and TRF2 during telomere-damage signalling and cellular senescence

C. Harris, E. Appella, D. Lane, 2010, Nature Cell Biology.

Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.

J. Bartek, D. Lane, J. Gannon, 1990, Oncogene.

Cancer: Awakening angels

D. Lane, D Lane, 1998, Nature.

High levels of p53 protein in UV-irradiated normal human skin.

D. Lane, P. Hall, P. H. Mckee, 1993, Oncogene.

p53 and human cancers.

D. Lane, 1994, British medical bulletin.

A “spindle and thread”-mechanism unblocks translation of N-terminally disordered proteins

J. Johansson, D. Lane, R. Zubarev, 2021, bioRxiv.

Enhancing Specific Disruption of Intracellular Protein Complexes by Hydrocarbon Stapled Peptides Using Lipid Based Delivery

C. Brown, D. Lane, C. Johannes, 2017, Scientific Reports.

Enhancing the therapeutic effects of in vitro targeted radionuclide therapy of 3D multicellular tumor spheroids using the novel stapled MDM2/X-p53 antagonist PM2

D. Lane, C. Brown, M. Nestor, 2020, EJNMMI Research.

Mutational spectra and immunohistochemical analyses of p53 in human cancers.

B. Vogelstein, C. Harris, M. Hollstein, 1992, Chest.

Stress, specificity and the NEDD8 proteome

D. Lane, 2012, Cell cycle.

p53 expression and prognosis in gastric carcinoma

D. Lane, M. Filipe, Hilary M. Martin, 1992, International journal of cancer.

p53 and DNA polymerase α compete for binding to SV40 T antigen

D. Lane, J. Gannon, Julian Gannon, 1987, Nature.

Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas.

W. J. Brammar, D. Lane, J. Varley, 1991, Oncogene.

Comparison between p53 staining in tissue sections and p53 proteins levels measured by an ELISA technique.

D. Lane, B. Vojtesek, D. Barnes, 1993, British Journal of Cancer.

The relationship of p53 immunostaining to survival in carcinoma of the lung.

D. Lane, K. Gatter, M. Dunnill, 1992, British Journal of Cancer.

Lowp53 protein expression in salivary gland tumours compared with lung carcinomas

D. Lane, Y. Soini, K. Vähäkangas, 2005, Virchows Archiv A.

p53 is phosphorylated at the carboxyl terminus and promotes the differentiation of human HaCaT keratinocytes

E. Lane, J. Jorcano, D. Lane, 2000, Molecular carcinogenesis.

Regulation of p 53 protein expression in human breast cancer cell lines

D. Lane, B. Vojtesek, B. Vojtěšek, 2022 .

Requirement for the replication protein SSB in human DMA excision repair

D. Lane, R. Wood, D. Coverley, 1991, Nature.

Protein interactions at the carboxyl terminus of p53 result in the induction of its in vitro transactivation potential

B. Groner, D. Lane, S. Hansen, 1997, Oncogene.

Identification du site d'interaction de p21waf1 dans pcna (antigene nucleaire a cellules proliferatives) et ses applications therapeutiques

D. Lane, L. Cox, D. Glover, 1995 .

The Immune Response to p 53 in Breast Cancer Patients Is Directed against Immunodominant Epitopes Unrelated to the Mutational Hot Spot 1

D. Lane, M. Marty, T. Soussi, 1992 .

Over‐expression of p53 nuclear oncoprotein in colorectal adenomas

W. Bodmer, G. Stamp, D. Lane, 1992, International journal of cancer.

Def defines a conserved nucleolar pathway that leads p53 to proteasome-independent degradation

D. Lane, Jinrong Peng, Jun Chen, 2013, Cell Research.

Identification of pathways modulating vemurafenib resistance in melanoma cells via a genome-wide CRISPR/Cas9 screen

D. Lane, C. Coffill, J. H. Wong, 2020, bioRxiv.

Nutlin-3 inhibits the NFκB Pathway in a p53 Dependent Manner: Implications in Lung Cancer Therapy

D. Lane, A. Dey, P. Bist, 2007, Cell cycle.

Linkage studies in a Li-Fraumeni family with increased expression of p53 protein but no germline mutation in p53.

D. Lane, M. Santibanez-Koref, M. Teare, 1994, British Journal of Cancer.

De-risking Drug Discovery of Intracellular Targeting Peptides: Screening Strategies to Eliminate False-Positive Hits.

Nils A. Berglund, D. Lane, C. Verma, 2020, ACS medicinal chemistry letters.

Constitutional mutation in exon 8 of the p53 gene in a patient with multiple primary tumours: molecular and immunohistochemical findings.

M. Stratton, R. Eeles, D. Easton, 1993, Oncogene.

Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity.

I. Cree, D. Lane, P. Andreotti, 1994, Biochemical and biophysical research communications.

Conformational ordering of intrinsically disordered peptides for targeting translation initiation

D. Lane, C. Verma, Dilraj Lama, 2020, bioRxiv.

Benzene Probes in Molecular Dynamics Simulations Reveal Novel Binding Sites for Ligand Design

M. Noble, D. Lane, Y. S. Tan, 2016, The journal of physical chemistry letters.

Mdm 2 in Evolution

D. Lane, C. Verma, 2012 .

Systematic mutational analysis of an ubiquitin ligase (MDM2)-binding peptide: computational studies

D. Lane, C. Verma, Yun Liu, 2011 .

Monoclonal Antibodies against Specific p53 Hotspot Mutants as Potential Tools for Precision Medicine.

D. Lane, K. Sabapathy, O. Liew, 2018, Cell reports.

Inhibition of cell proliferation by the PCNA-binding region of p21 expressed as a GFP miniprotein.

D. Lane, E. Warbrick, H. Mattock, 2001, Experimental cell research.

Epitope Mapping of Antibodies Recognising the N-Terminal Domain of Simian Virus Large Tumour Antigen

D. Lane, M. Kenny, S. Mole, 1998, Intervirology.

A unique role for p53 in the regulation of M2 macrophage polarization

F. Ginhoux, S. Leow, D. Lane, 2014, Cell Death and Differentiation.

Improving cancer therapy by non-genotoxic activation of p53.

D. Lane, S. Laín, D. Lane, 2003, European journal of cancer.

A study of cell proliferation in formalin‐fixed, wax‐embedded bone marrow trephine biopsies using the monoclonal antibody PC10, reactive with proliferating cell nuclear antigen (PCNA)

D. Lane, D. Jones, N. Waseem, 1992, The Journal of pathology.

Worrying about p53

D. Lane, 1992, Current Biology.

DNA Mediated Gene Transfer: Theory and Application

M. Wigler, D. Hanahan, M. Botchan, 1980 .

Monoclonal antibody analysis of p53 expression in normal and transformed cells

J. Yewdell, D. Lane, J. Gannon, 1986, Journal of virology.

Two different viral transforming proteins bind the same host tumour antigen

D. Lane, E. Harlow, 1982, Nature.

Targeting the cell cycle

D. Lane, P. Fischer, D. Glover, 2004 .

Expression of p53 in premalignant and malignant squamous epithelium.

B. Gusterson, H. Jayatilake, D. Lane, 1991, Oncogene.

Characterization of human p53 antigens employing primate specific monoclonal antibodies.

A. Levine, D. Lane, N. Reich, 1983, Virology.

Cellular delivery of impermeable effector molecules in the form of conjugates with peptides capable of mediating membrane translocation.

D. Lane, P. Fischer, E. Krausz, 2001, Bioconjugate chemistry.

The hot-spot p53R172H mutant promotes formation of giant spermatogonia triggered by DNA damage

D. Lane, E. Wong, Y. Xue, 2016, Oncogene.

Scotin: A new p63 target gene expressed during epidermal differentiation

R. Knight, G. Melino, D. Lane, 2008, Biochemical and biophysical research communications.

Identification of the RNA2 protein of Saccharomyces cerevisiae

D. Lane, J. Beggs, Melanie G. Lee, 1986, Yeast.

Chromosome mapping of the human gene encoding the 68-kDa nuclear antigen (p68) by using the polymerase chain reaction.

D. Lane, R. Iggo, N. Spurr, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Enlarged family of putative helicases

D. Lane, 1988, Nature.

Differential expression of p53, p21waf1/cip1 and hdm2 dependent on DNA damage in Bloom's syndrome fibroblasts.

B. Kuehl, D. Lane, M. Collister, 1998, Carcinogenesis.

Archival analysis of p53 genetic and protein alterations in Chinese esophageal cancer.

R. Metcalf, M. Hollstein, D. Lane, 1991, Oncogene.

Cancer. A death in the life of p53.

D. Lane, 1993, Nature.

Localization of p53, retinoblastoma and host replication proteins at sites of viral replication in herpes-infected cells

D. Lane, D. Wilcock, Diane Wilcock, 1991, Nature.

p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes.

C. Harris, E. Appella, M. Blasco, 2013, The Journal of clinical investigation.

Expression of mutant p53 in melanoma.

A. Harris, D. Lane, K. Gatter, 1991, Cancer research.

Expression of Mutant p 53 in Melanoma Updated

A. Harris, D. Lane, K. Gatter, 2006 .

An immunocytochemical study of p53 and bcl-2 protein expression in Hodgkin's disease.

D. Lane, D. Mason, K. Gatter, 1993, American journal of clinical pathology.

Rapid recruitment of p53 to DNA damage sites directs DNA repair choice and integrity

May Yin Lee, Hui Chin Goh, W. Tam, 2022, Proceedings of the National Academy of Sciences of the United States of America.

Use of peptides from p21 (Waf1/Cip1) to investigate PCNA function in Xenopus egg extracts.

P. Jares, D. Lane, D. Zheleva, 2001, Experimental cell research.

Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit.

D. Lane, D. Zheleva, P. Fischer, 2003, Current medicinal chemistry. Anti-cancer agents.

Incorporation of Putative Helix-Breaking Amino Acids in the Design of Novel Stapled Peptides: Exploring Biophysical and Cellular Permeability Properties

Mohan R. Pradhan, D. Lane, J. Hochman, 2019, Molecules.

Gene therapy for gastric cancer: problems and prospects.

D. Lane, R. Steele, 2000, Surgical oncology.

Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder.

D. Neal, D. Lane, C. Horne, 1991, British Journal of Cancer.

Expression ofmutantp53, c-erbB-2 andtheepidermal growth factor receptor intransitional cell carcinoma ofthehumanurinary bladder

D. Neal, D. Lane, C. Horne, 1991 .

Dominant nonresponsiveness in the induction of autoimmunity to liver- specific F antigen

D. Lane, D. Silver, 1975, The Journal of experimental medicine.

Hypophosphorylation of Mdm2 Augments p53 Stability

D. Lane, C. Blattner, D. Meek, 2002, Molecular and Cellular Biology.

Detecting p53 isoforms at protein level.

D. Lane, J. Bourdon, K. Fernandes, 2013, Methods in molecular biology.

p53 Protein alterations in human testicular cancer including pre‐invasive intratubular germ‐cell neoplasia

J. Bartek, J. Lukas, J. Kovarik, 1991, International journal of cancer.

Immunohtstochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies

J. Bartek, J. Lukas, J. Bártková, 1993, The Journal of pathology.

Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma.

D. Eccles, D. Lane, C. Steel, 1992, British Journal of Cancer.

Simian virus 40 large T-antigen-dependent DNA replication is activated by protein phosphatase 2A in vitro

D. Lane, P. Cohen, R. Lawson, 1990, Journal of virology.

Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein.

J. Kovarik, D. Lane, B. Vojtesek, 1995, Oncogene.

Expression of Mutant p53 in Melanoma1

A. Harris, D. Lane, Jonathan, 2006 .

Expression of Mutant p 53 in Melanoma 1

A. Harris, D. Lane, K. Gatter, 2006 .

Corrigendum to ‘Understanding p53 functions through p53 antibodies’

D. Lane, K. Sabapathy, 2019, Journal of molecular cell biology.

Radiation-induced astrocyte senescence is rescued by &Dgr;133p53

C. Harris, D. Lane, B. Vojtesek, 2019, Neuro-oncology.

Mass Spectrometry Reveals the Direct Action of a Chemical Chaperone.

E. Marklund, J. Johansson, D. Lane, 2018, The journal of physical chemistry letters.

T antigen is bound to a host protein in SY40-transformed cells

D. Lane, L. Crawford, 1979, Nature.

Monoclonal antibody analysis of simian virus 40 small t-antigen expression in infected and transformed cells

D. Lane, X. Montano, 1989, Journal of Virology.

Oncogenic intelligence: Cell immortalization and transformation by the p53 gene

D. Lane, 1984, Nature.

The complex between simian virus 40 T antigen and a specific host protein

D. Lane, L. Crawford, 1980, Proceedings of the Royal Society of London. Series B. Biological Sciences.

An immunochemical investigation of SV40 T-antigens. 2. Quantitation of antigens and antibody activities.

D. Lane, D. Pim, L. Crawford, 1980, Virology.

An immunochemical investigation of SV40 T antigens. 1. Production properties and specificity of rabbit antibody to purified simian virus 40 large-T antigen.

D. Lane, A. Robbins, 1978, Virology.

Comparative analysis ofp53 protein immunoreactivity in prostatic, lung and breast carcinomas

D. Lane, Y. Soini, K. Vähäkangas, 2005, Virchows Archiv A.

Author Correction: The effects of Antibody Engineering CH and CL in Trastuzumab and Pertuzumab recombinant models: Impact on antibody production and antigen-binding

D. Lane, J. Yeo, S. Gan, 2018, Scientific Reports.

Expression of p53 protein in invasive colorectal carcinomas of different histologic types

D. Lane, M. Hanski, E. Riecken, 1992, Cancer.

The adenovirus Ela gene induces differentiation of F9 teratocarcinoma cells

D. Lane, X. Montano, 1987, Molecular and cellular biology.

Combined proinflammatory cytokine and cognate activation of invariant natural killer T cells enhances anti-DNA antibody responses

D. Lane, R. Holmdahl, S. Sedimbi, 2020, Proceedings of the National Academy of Sciences.

Monoclonal antibody to simian virus 40 small t

D. Lane, X. Montano, 1984, Journal of virology.

Drug discovery and target validation in the p53 pathway

D. Lane, 2009 .

Coming to terms with death: apoptosis in cancer and immune development.

S. Korsmeyer, D. Lane, J. Cidlowski, 1994, Immunology today (Amsterdam. Regular ed.).

The p53 response to ionising radiation in adult and developing murine tissues.

A. Balmain, D. Lane, F. Walsh, 1996, Oncogene.

Immunohistochemical and Ultrastructural Evidence for Myelopoiesis in the Scid/scid Mouse Thymus

D. Lane, U. Schumacher, M. Kendall, 1999, The Histochemical Journal.

Proliferating cell nuclear antigen expression in non-cycling cells may be induced by growth factors in vivo.

D. Lane, P. Hall, P. Coates, 1994, British Journal of Cancer.

Chaperone-dependent stabilization and degradation of p53 mutants

D. Lane, B. Vojtesek, D. Coomber, 2008, Oncogene.

p53 Pathway and Cancer Therapy

D. Lane, C. F. Cheok, 2012 .

Conservation of all three p53 family members and Mdm2 and Mdm4 in the cartilaginous fish

S. Brenner, B. Venkatesh, B. Tay, 2011, Cell cycle.

Epitope mapping using bacteriophage peptide libraries.

D. Lane, C. Stephen, 1993, Current opinion in immunology.

Characterization of the complex between SV40 large T antigen and the 53K host protein in transformed mouse cells.

D. Lane, D. Pim, E. Harlow, 1980, Cold Spring Harbor symposia on quantitative biology.

The p16(INK4a) tumour suppressor protein inhibits alphavbeta3 integrin-mediated cell spreading on vitronectin by blocking PKC-dependent localization of alphavbeta3 to focal contacts.

R. Fåhraeus, D. Lane, 1999, The EMBO journal.

Flow cytometric characterisation of proliferating cell nuclear antigen using the monoclonal antibody PC10.

D. Lane, G. Wilson, R. Camplejohn, 1992, European journal of cancer.

p53: out of Africa

D. Lane, 2016, Genes & Development.

Monoclonal antibodies to a proenkephalin A fusion peptide synthesized in Escherichia coli recognize novel proenkephalin A precursor forms.

D. Lane, D. Glover, B. Spruce, 1988, The Journal of biological chemistry.

Investigating the Specificity of Monoclonal Antibodies to Protein Antigens Using β-Galactosidase Fusion Proteins

D. Lane, J. Gannon, S. Mole, 1985 .

Expression of the p53 protein in a spectrum of astrocytic tumours

D. Ellison, D. Lane, K. Gatter, 1992, The Journal of pathology.

EXPRESSION OF P53, C-ERBB-2 AND THE EPIDERMAL GROWTH-FACTOR RECEPTOR IN TRANSITIONAL CELL CARCINOMAS OF THE BLADDER

D. Neal, D. Lane, K. Mellon, 1991 .

Regulation of the specific DNA binding function of p53

D. Lane, T. Hupp, C. Midgley, 1992, Cell.

Molecular events including p53 and k-ras alterations in the in vitro progression of a human colorectal adenoma cell line to an adenocarcinoma.

D. Lane, C. Marshall, C. Paraskeva, 1993, Oncogene.

MDM2 inhibitors, nutlin-3a and navtemadelin, retain efficacy in human and mouse cancer cells cultured in hypoxia

D. Lane, B. Vojtesek, P. Kannan, 2022, bioRxiv.

A yeast two-hybrid system for the screening and characterization of small-molecule inhibitors of protein–protein interactions identifies a novel putative Mdm2-binding site in p53

D. Lane, C. Verma, J. H. Wong, 2017, BMC Biology.

Immunological cross-reaction between large T-antigens of SV40 and polyoma virus.

F. McCormick, D. Lane, S. Dilworth, 1982, Virology.

CRISPR enriches for cells with mutations in a p53-related interactome, and this can be inhibited

D. Lane, F. Wermeling, S. Sedimbi, 2021, bioRxiv.

Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: An index of cell proliferation with evidence of deregulated expression in some, neoplasms

D. Lane, R. Camplejohn, P. Hall, 1990, The Journal of pathology.

A death in the life of p53

D. Lane, 1993, Nature.

A comparison and optimization of methods and factors affecting the transformation of Escherichia coli

D. Lane, C. Verma, W. Chan, 2013, Bioscience reports.

Identification of novel mdm2 binding peptides by phage display.

D. Lane, C. García-echeverría, P. Chène, 1996, Oncogene.

Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1.

D. Lane, D. Maccallum, A. Gianella-Borradori, 2005, Cancer research.

Macrocyclic α helical peptide therapeutic modality: A perspective of learnings and challenges.

A. Peier, D. Lane, J. Hochman, 2018, Bioorganic & medicinal chemistry.

Drugging the p53 pathway: understanding the route to clinical efficacy

D. Lane, K. Khoo, C. Verma, 2014, Nature Reviews Drug Discovery.

Stapled peptides with improved potency and specificity that activate p53.

D. Lane, C. Verma, C. Brown, 2013, ACS chemical biology.

Immunohistochemical detection of p53 and bcl‐2 proteins in non‐Hodgkin's lymphoma

D. Lane, F. Pezzella, A. Harris, 1993, Histopathology.

p53 expression in dyskeratosis congenita: a marker for oral premalignancy?

D. Lane, G. Ogden, D. Chisholm, 1993, Journal of clinical pathology.

The MDM2/MDMX-p53 Antagonist PM2 Radiosensitizes Wild-Type p53 Tumors.

D. Lane, C. Brown, D. Spiegelberg, 2018, Cancer research.

p53 protein expression in benign and malignant skin tumours

D. Lane, D. Harrison, J. Rees, 1993, The British journal of dermatology.

The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice.

C J Kemp, A. Balmain, D. Lane, 1994, Cancer research.

Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies.

J. Bartek, J. Lukas, J. Bártková, 1991, Oncogene.

Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form.

D. Lane, N. Waseem, D. Lane, 1990, Journal of cell science.

SV40 large T shares an antigenic determinant with a cellular protein of molecular weight 68,000

D. Lane, D. P. Lane, W. K. Hoeffler, 1980, Nature.

Suppression of the Deubiquitinating Enzyme USP5 Causes the Accumulation of Unanchored Polyubiquitin and the Activation of p53*

D. Lane, M. Saville, A. Sparks, 2009, Journal of Biological Chemistry.

Absence of p53 autoantibodies in a significant proportion of breast cancer patients.

J. Kovarik, D. Lane, B. Vojtesek, 1995, British Journal of Cancer.

Diverse p63 and p73 isoforms regulate Δ133p53 expression through modulation of the internal TP53 promoter activity

D. Lane, J. Bourdon, K. Fernandes, 2011, Cell Death and Differentiation.

A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction

D. Lane, N. Wright, P. Hall, 1991, The Journal of pathology.

Nutlin-3 sensitizes nasopharyngeal carcinoma cells to cisplatin-induced cytotoxicity

D. Lane, R. Husaini, Munirah Ahmad, 2015, Oncology reports.

An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53.

J. Bartek, D. Lane, B. Vojtesek, 1992, Journal of immunological methods.

Regulation of p53 protein expression in human breast cancer cell lines.

D. Lane, B. Vojtesek, D. Lane, 1993, Journal of cell science.

Molecular recognition and the future of monoclonal antibodies

David Lane, D. Lane, H. Koprowski, 1982, Nature.

High efficiency gene transfer into mammalian cells.

P. Rigby, D. Lane, C. Gorman, 1984, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

Prognostic value of proliferating cell nuclear antigen in gastric carcinoma.

D. Lane, P. Hall, D. Levison, 1991, Journal of clinical pathology.

C-terminal phosphorylation of Hsp70 and Hsp90 regulates alternate binding to co-chaperones CHIP and HOP to determine cellular protein folding/degradation balances

D. Lane, E. Růčková, B. Vojtesek, 2013, Oncogene.

Genetics of growth arrest and cell death: key determinants of tissue homeostasis.

D. Lane, P. Hall, 1994, European journal of cancer.

Cancer. p53, guardian of the genome.

D. Lane, D P Lane, 1992, Nature.

p53 In tumour pathology: Can we trust immunohistochemistry?—revisited!

D. Lane, P. Hall, 1994, The Journal of pathology.

A role for the human single-stranded DNA binding protein HSSB/RPA in an early stage of nucleotide excision repair.

D. Lane, R. Wood, D. Coverley, 1992, Nucleic acids research.

An immunoaffinity purification procedure for SV40 large T antigen.

D. Lane, V. Simanis, Viesturs Simanis, 1985, Virology.

Novel cambinol analogs as sirtuin inhibitors: synthesis, biological evaluation, and rationalization of activity.

A. Slawin, D. Lane, N. Westwood, 2009, Journal of medicinal chemistry.

Epithelial proliferation in Barrett's esophagus by proliferating cell nuclear antigen immunolocalization.

D. Lane, P. Hall, B. Ansari, 1992, Gastroenterology.

Constitutive activation of WASp in X-linked neutropenia renders neutrophils hyperactive

Minghui He, S. Snapper, D. Lane, 2018, The Journal of clinical investigation.

Two Pathways for Base Excision Repair in Mammalian Cells (*)

D. Lane, L. Cox, E. Dogliotti, 1996, The Journal of Biological Chemistry.

p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding

D. Lane, C. Midgley, 1997, Oncogene.

A quantitative study of the in vitro binding of the C-terminal domain of p21 to PCNA: affinity, stoichiometry, and thermodynamics.

D. Lane, D. Zheleva, P. Fischer, 2000, Biochemistry.

Abnormal expression of wild type p53 protein in normal cells of a cancer family patient

D. Lane, L. Bobrow, B. Vojtesek, 1992, The Lancet.

A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival.

David P Lane, T. Stankovic, C. Fegan, 2005, Blood.

A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma.

S. Nelander, D. Lane, C. Vinel, 2020, Cell reports.

Activation of p53 in cervical carcinoma cells by small molecules.

D. Lane, C. Blattner, S. Hietanen, 2000, Proceedings of the National Academy of Sciences of the United States of America.

CD36 and LC3B initiated autophagy in B cells regulates the humoral immune response

Minghui He, D. Lane, S. Sedimbi, 2021, Autophagy.

Accumulating active p53 in the nucleus by inhibition of nuclear export: a novel strategy to promote the p53 tumor suppressor function.

D. Lane, D. Xirodimas, S. Laín, 1999, Experimental cell research.

Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors.

D. Lane, R. Jackson, D. Zheleva, 2010, Journal of medicinal chemistry.

Cell differentiation and chemotherapy influence p53 and Mdm2 immunoreactivity in human HT29 colon cancer cells grown in scid mice.

D. Lane, U. Schumacher, E. Adam, 2001, Cancer letters.

Small Molecular Weight Variants of p53 Are Expressed in Human Melanoma Cells and Are Induced by the DNA-Damaging Agent Cisplatin

Borivoj Vojtesek, Rodney J Scott, David P Lane, 2008, Clinical Cancer Research.

Discovery, In Vivo Activity, and Mechanism of Action of a Small-Molecule p53 Activator

Lee Baker, Alastair Thompson, Sonia Lain, 2007, Cancer cell.

Supplemental Data Discovery, in Vivo Activity, and Mechanism of Action of a Small-molecule P53 Activator Supplemental Experimental Procedures

A. Thompson, D. Lane, N. Westwood, 2022 .

The promise of molecular oncology

D. Lane, 1998, The Lancet.

Developing new treatments for breast cancer

D. Lane, 2004, Breast Cancer Research.

Intratumour heterogeneity of p53 expression; causes and consequences

D. Lane, Yuezhen Xue, Boris B San Luis, 2019, The Journal of pathology.

Design of a novel MDM2 binding peptide based on the p53 family

D. Lane, C. Verma, A. Madhumalar, 2009, Cell cycle.

Comparative study of the p53-mdm2 and p53-MDMX interfaces

Yolande F M Ramos, A. Jochemsen, D. Lane, 1999, Oncogene.

MDM2--arbiter of p53's destruction.

D. Lane, P. Hall, David P. Lane, 1997, Trends in biochemical sciences.

MDM4 downregulates p53 transcriptional activity and response to stress during differentiation

Kee Woei Ng, David P Lane, D. Lane, 2011, Cell cycle.

Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells

D. Lane, R. Kiessling, J. Ravetch, 2020, Proceedings of the National Academy of Sciences.

A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen

D. Lane, L. Cox, D. Glover, 1995, Current Biology.

Expression of p53 protein in infiltrating and in‐situ breast carcinomas

D. Lane, J. Varley, R. Walker, 1991, The Journal of pathology.

Novel p53-Based Therapies: Strategies and Future Prospects

D. Lane, S. Laín, 2007 .

PCNA binding proteins in Drosophila melanogaster : the analysis of a conserved PCNA binding domain.

D. Lane, D. Glover, E. Warbrick, 1998, Nucleic acids research.

Allosteric activation of latent p53 tetramers

D. Lane, T. Hupp, 1994, Current Biology.

New approaches to cancer therapies

R. Fåhraeus, D. Lane, E. Krausz, 1999, The Journal of pathology.

Cancer Cells Shuttle Extracellular Vesicles Containing Oncogenic Mutant p53 Proteins to the Tumor Microenvironment

D. Lane, K. Sabapathy, T. Cooks, 2021, Cancers.

p53 protein accumulates frequently in early bronchial neoplasia.

R. Metcalf, J. Samet, Y. Takeshima, 1993, Cancer research.

Regulation of the p14ARF promoter by DNA methylation

D. Lane, D. Coomber, S. Ménendez, 2008, Cell cycle.

Detection of the p53 response in zebrafish embryos using new monoclonal antibodies

E. Lane, D. Lane, B. Vojtesek, 2008, Oncogene.

Exploiting the p53 pathway for the diagnosis and therapy of human cancer.

D. Lane, D. Lane, 2005, Cold Spring Harbor symposia on quantitative biology.

Cellular localization and T antigen binding of the retinoblastoma protein.

J. Bartek, D. Lane, B. Vojtesek, 1992, Oncogene.

p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress

D. Lane, J. Bourdon, F. Murray-Zmijewski, 2006, Cell Death and Differentiation.

Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo

David P. Lane, D. Lane, Wei-Li Liu, 1997, Current Biology.

Curing cancer with p53.

D. Lane, 2004, The New England journal of medicine.

Rational design and biophysical characterization of thioredoxin-based aptamers: insights into peptide grafting.

Shubhra Ghosh Dastidar, Chandra Verma, Christopher J Brown, 2010, Journal of molecular biology.

An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo

D. Lane, M. Saville, R. Hay, 2000, Oncogene.

A novel unstructured scaffold based on 4EBP1 enables the functional display of a wide range of bioactive peptides.

D. Lane, Hai Yun See, 2010, Journal of molecular biology.

MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism

A. Thompson, D. Lane, C. Purdie, 2008, BMC Cancer.

Targeting ATM pathway for therapeutic intervention in cancer

Hilal S. Khalil, D. Lane, N. Zhelev, 2012 .

Tumor-specific signaling to p53 is mimicked by Mdm2 inactivation in zebrafish: insights from mdm2 and mdm4 mutant zebrafish

D. Lane, H. P. Liew, J. Chua, 2015, Oncogene.

Detection of the 113p53 protein isoform: A p53-induced protein that feeds back on the p53 pathway to modulate the p53 response in zebrafish

D. Lane, F. Ghadessy, D. Coomber, 2010, Cell cycle.

Tumor susceptibility and apoptosis defect in a mouse strain expressing a human p53 transgene.

E. Appella, A. Fornace, D. Lane, 2006, Cancer research.

Regulation of p53 by the Ubiquitin-conjugating Enzymes UbcH5B/C in Vivo*

D. Lane, M. Saville, J. Bourdon, 2004, Journal of Biological Chemistry.

p53 from pathway to therapy

D. Lane, 2004 .

Turning the key on p53

D. Lane, P. Fischer, 2004, Nature.

Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo.

D. Lane, P. Hall, C. Midgley, 1995, Journal of cell science.

p68 RNA helicase: identification of a nucleolar form and cloning of related genes containing a conserved intron in yeasts

D. Lane, J. Southgate, R. Iggo, 1991, Molecular and cellular biology.

Nuclear protein with sequence homology to translation initiation factor eIF-4A

D. Lane, I. Anton, M. Ford, 1988, Nature.

Synthetic 10FN3-based mono- and bivalent inhibitors of MDM2/X function

D. Lane, J. Siau, F. Ghadessy, 2018, Protein engineering, design & selection : PEDS.

Structure-activity studies of Mdm2/Mdm4-binding stapled peptides comprising non-natural amino acids

D. Lane, J. Siau, F. Ghadessy, 2017, PloS one.

Title In vitro selection of mutant HDM 2 resistant to nutlininhibition

Adelene Y. L. Sim, D. Lane, C. Verma, 2017 .

Title Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm 2

D. Lane, C. Verma, F. Ghadessy, 2017 .

Functional characterization of p53 pathway components in the ancient metazoan Trichoplax adhaerens

D. Lane, Y. S. Tan, C. Verma, 2016, Scientific Reports.

A highly sensitive fluorescent light-up probe for real-time detection of the endogenous protein target and its antagonism in live cells.

B. Liu, D. Lane, F. Ghadessy, 2015, Journal of materials chemistry. B.

Structure of a Stapled Peptide Antagonist Bound to Nutlin-Resistant Mdm2

D. Lane, C. Verma, F. Ghadessy, 2014, PloS one.

Isg15 controls p53 stability and functions

D. Lane, D. Bulavin, Sheena Wee, 2014, Cell cycle.

High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemia

T. Lim, D. Lane, K. Khoo, 2013, Oncotarget.

In Vitro Selection of Mutant HDM2 Resistant to Nutlin Inhibition

Adelene Y. L. Sim, D. Lane, C. Verma, 2013, PloS one.

The deubiquitinating enzyme USP 2 a regulates the p 53 pathway by targeting Mdm 2

D. Lane, M. Saville, D. Xirodimas, 2013 .

The p53 isoforms are differentially modified by Mdm2

D. Lane, J. Bourdon, K. Fernandes, 2012, Cell cycle.

Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis

D. Lane, Jaewang Ghim, M. Lee, 2009, The EMBO journal.

Nuclear export inhibitor leptomycin B induces the appearance of novel forms of human Mdm2 protein

D. Lane, S. Laín, M. Higgins, 2003, British Journal of Cancer.

Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo

D. Lane, M. Saville, D. Xirodimas, 2001, Oncogene.

An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs.

E. Lane, D. Lane, C. Midgley, 1999, Experimental cell research.

Activation of the cryptic DNA binding function of mutant forms of p53.

D. Lane, T. Hupp, C. Midgley, 1993, Nucleic acids research.

Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets?

D. Lane, P. Fischer, 2004, Trends in pharmacological sciences.

p53 isoforms regulate premature aging in human cells

C. Harris, D. Lane, I. Horikawa, 2017, Oncogene.

Stapled peptide design: principles and roles of computation.

Chandra S Verma, Yaw Sing Tan, David P Lane, 2016, Drug Discovery Today.

Mutations in p53 are frequent in the preneoplastic stage of mouse mammary tumor development.

F. Kittrell, D. Lane, D. J. Jerry, 1993, Cancer research.

Enhancing Specific Disruption of Intracellular Protein Complexes by Hydrocarbon Stapled Peptides Using Lipid Based Delivery

C. Brown, D. Lane, C. Johannes, 2017, Scientific Reports.

Functionalised staple linkages for modulating the cellular activity of stapled peptides

D. Spring, L. Itzhaki, D. Lane, 2014 .

Stapled BH3 Peptides against MCL-1: Mechanism and Design Using Atomistic Simulations

D. Lane, C. Verma, T. Joseph, 2012, PloS one.

Reactivation of p53: from peptides to small molecules.

D. Lane, C. Verma, C. F. Cheok, 2011, Trends in pharmacological sciences.

p53-based cancer therapy.

David P Lane, Sonia Lain, D. Lane, 2010, Cold Spring Harbor perspectives in biology.

Rigorous Computational and Experimental Investigations on MDM2/MDMX-Targeted Linear and Macrocyclic Peptides

Jon Swanson, Alexander S. Bayden, Joseph Audie, 2019, Molecules.

Simultaneous measurement of p53:Mdm2 and p53:Mdm4 protein-protein interactions in whole cells using fluorescence labelled foci

C. Brown, D. Lane, Y. Frosi, 2019, Scientific Reports.

Investigating peptide sequence variations for 'double-click' stapled p53 peptides.

D. Spring, D. Lane, G. McKenzie, 2014, Organic & biomolecular chemistry.

Mechanism of Stapled Peptide Binding to MDM2: Possible Consequences for Peptide Design.

Adelene Y. L. Sim, D. Lane, C. Verma, 2014, Journal of chemical theory and computation.

Modulating the p53 pathway.

D. Lane, C. Verma, A. Dey, 2010, Seminars in cancer biology.

MdmX is a substrate for the deubiquitinating enzyme USP2a

D. Lane, M. Saville, A. Sparks, 2010, Oncogene.

Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy

A. Thompson, D. Lane, S. Laín, 2010, Oncotarget.

Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53

D. Lane, C. F. Cheok, P. Kaldis, 2010, Cell Death and Differentiation.

p53 mutation and protein accumulation during multistage human esophageal carcinogenesis.

R. Metcalf, M. Hollstein, D. Lane, 1992, Cancer research.

Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion

J. Norman, D. Lane, P. Timpson, 2012, Oncogene.

The Role of Fluorescence In Situ Hybridization Technologies in Molecular Diagnostics and Disease Management

Jim Piper, Walter King, J. Piper, 2000, Molecular Diagnosis.

Drug discovery and p53.

D. Lane, T. Hupp, 2003, Drug discovery today.

New developments in small molecules targeting p53 pathways in anticancer therapy

D. Lane, C. F. Cheok, 2008 .

Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B

E. Lane, D. Lane, C. Midgley, 1999, Oncogene.

Using targeted transgenic reporter mice to study promoter-specific p53 transcriptional activity

Michael B. Mann, D. Lane, A. Goh, 2012, Proceedings of the National Academy of Sciences.

Development of a novel multiplex in vitro binding assay to profile p53-DNA interactions

D. Lane, F. Ghadessy, W. Goh, 2010, Cell cycle.

Small peptides activate the latent sequence-specific DNA binding function of p53

D. Lane, T. Hupp, A. Sparks, 1995, Cell.

The Role of p 53 in Spontaneous and Radiation-induced Apoptosis in the Gastrointestinal Tract of Normal and p 53-deficient Mice 1

A. Balmain, D. Lane, A. Merritt, 2006 .

Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-κB pathways

D. Lane, A. Dey, V. Tergaonkar, 2008, Nature Reviews Drug Discovery.

R-Roscovitine simultaneously targets both the p53 and NF-κB pathways and causes potentiation of apoptosis: implications in cancer therapy

D. Lane, C. F. Cheok, E. Wong, 2007, Cell Death and Differentiation.

Host proteins that bind to or mimic SV40 large T antigen: using antibodies to look at protein interactions and their significance.

D. Lane, J. Gannon, I. Anton, 1989, Immunology. Supplement.

HEXIM1 and the Control of Transcription Elongation: From Cancer and Inflammation to AIDS and Cardiac Hypertrophy

D. Lane, A. Dey, S. Chao, 2007, Cell cycle.

Scotin, a novel p53-inducible proapoptotic protein located in the ER and the nuclear membrane

D. Lane, J. Bourdon, K. Fernandes, 2002, The Journal of cell biology.

Specific activation of the p53 pathway by low dose actinomycin D: A new route to p53 based cyclotherapy

D. Lane, Henry Yang, M. Choong, 2009, Cell cycle.

Activation of p53 by scaffold-stabilised expression of Mdm2-binding peptides: visualisation of reporter gene induction at the single-cell level

D. Lane, L. Stevenson, G. Karlsson, 2004, British Journal of Cancer.

p53-Mediated Radiosensitization of 177Lu-DOTATATE in Neuroblastoma Tumor Spheroids

S. Nelander, D. Lane, Preeti Jha, 2021, Biomolecules.

Identification of the gene locus controlling dominant nonresponsiveness to F-antigen

D. Lane, D. Silver, 1977, Immunogenetics.

Inhibition of lymphocyte proliferation by murine liver-specific F antigen.

D. Lane, D. Silver, 1977, Transplantation Proceedings.

Cyclin-Dependent Kinase Inhibitors Sensitize Tumor Cells to Nutlin-Induced Apoptosis : a Potent Drug Combination Chit

D. Lane, A. Dey, Fang Cheok, 2007 .

A hierarchy of responsiveness and the production of nonprecipitating antibodies to F antigen

D. Lane, D. Silver, 1979, Immunogenetics.

Polygenic control of the immune response to F antigen

D. Lane, D. Silver, 2005, Immunogenetics.

Mutant p53 accumulates in cycling and proliferating cells in the normal tissues of p53 R172H mutant mice

Michael B. Mann, D. Lane, N. Barker, 2015, Oncotarget.

De-risking drug discovery of intracellular targeting peptides: screening strategies to eliminate false-positive hits

Nils A. Berglund, D. Lane, C. Verma, 2019, bioRxiv.

Loss of function of def selectively up-regulates Delta113p53 expression to arrest expansion growth of digestive organs in zebrafish.

Zhenhai Zhang, D. Lane, Wei Wu, 2005, Genes & development.

Mdm2 and p53 are highly conserved from placozoans to man

D. Lane, C. Verma, A. Madhumalar, 2010, Cell cycle.

Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens.

D. Lane, P. Hall, S. Dowell, 1994, Cancer research.

p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients

A. Thompson, D. Lane, C. Purdie, 2011, Breast Cancer Research.

Exploiting the p53 Pathway for Therapy.

D. Lane, C. F. Cheok, 2017, Cold Spring Harbor perspectives in medicine.

NPMc+ AML cell line shows differential protein expression and lower sensitivity to DNA-damaging and p53-inducing anticancer compounds

Qiao Jing Lew, D. Lane, M. Gurumurthy, 2011, Cell cycle.

Autophagic flux blockage by accumulation of weakly basic tenovins leads to elimination of B-Raf mutant tumour cells that survive vemurafenib

Gergana Popova, D. Lane, N. Westwood, 2018, PloS one.

P53 abnormalities and outcomes in colorectal cancer: a systematic review

D. Lane, A. Munro, S. Laín, 2005, British Journal of Cancer.

Targeting a nucleolar SUMO protease for degradation: A mechanism by which ARF induces SUMO conjugation

D. Lane, D. Xirodimas, 2008 .

Targeting a nucleolar SUMO protease for dégradation

D. Lane, D. Xirodimas, 2008 .

The p53-Mdm2 pathway: targets for the development of new anticancer therapeutics.

D. Lane, D. Zheleva, P. Fischer, 2003, Mini reviews in medicinal chemistry.

Therapeutic exploitation of the p53 pathway.

D. Lane, S. Laín, 2002, Trends in molecular medicine.

Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein.

D. Lane, M. Saville, C. Midgley, 2001, Journal of molecular biology.

Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others

D. Lane, K. Sabapathy, 2018, Nature Reviews Clinical Oncology.

HPV-16 E7 or adenovirus E1A can overcome the growth arrest of cells immortalized with a temperature-sensitive p53.

D. Lane, K. Vousden, B. Vojtesek, 1993, Oncogene.

Protein synthesis required to anchor a mutant p53 protein which is temperature-sensitive for nuclear transport

David P. Lane, D. Lane, Julian V. Cannon, 1991, Nature.

Updates on p53: modulation of p53 degradation as a therapeutic approach

D. Lane, C. Verma, A. Dey, 2008, British Journal of Cancer.

Cyclin-Dependent Kinase Inhibitors Sensitize Tumor Cells to Nutlin-Induced Apoptosis: a Potent Drug Combination

David P Lane, D. Lane, C. F. Cheok, 2007, Molecular Cancer Research.

How the Other Half Lives: What p53 Does When It Is Not Being a Transcription Factor

D. Lane, T. Ho, Ban Xiong Tan, 2019, International journal of molecular sciences.

Influenza A Viruses Control Expression of Proviral Human p53 Isoforms p53β and Δ133p53α

D. Lane, J. Bourdon, V. Marcel, 2012, Journal of Virology.

Ionizing radiation induces a dramatic persistence of p53 protein accumulation and DNA damage signaling in mutant p53 zebrafish

E. Lane, D. Lane, A. Goh, 2013, Oncogene.

Tumour suppressors: A developing role for p53?

D. Lane, P. Hall, 1997, Current Biology.

The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma.

A. Cuschieri, D. Lane, B. Joypaul, 1994, British Journal of Cancer.

Inhibition of NLRP3 inflammasome activation by cell-permeable stapled peptides

D. Lane, C. Verma, Arumay Pal, 2019, Scientific Reports.

Growth factor stimulation of proliferating cell nuclear antigen (PCNA) in human breast epithelium in organ culture.

B. Gusterson, R. Nicholson, H. Jayatilake, 1991, Cell biology international reports.

The Fluorescent Two-Hybrid Assay to Screen for Protein–Protein Interaction Inhibitors in Live Cells

I. Stansfield, D. Lane, I. Hickson, 2014, Journal of biomolecular screening.

Targeting the Interaction of p 53 with Mdm 2 and Mdm 4 Protein Interaction Inhibitors in Live Cells : − The Fluorescent Two-Hybrid Assay to Screen for Protein

I. Stansfield, D. Lane, I. Hickson, 2014 .

Homologous regions of Fen1 and p21Cip1 compete for binding to the same site on PCNA: a potential mechanism to co-ordinate DNA replication and repair

D. Lane, L. Cox, D. Glover, 1997, Oncogene.

Exploiting the p53 pathway for cancer diagnosis and therapy.

D. Lane, D P Lane, D. Lane, 1999, British journal of cancer.

Cellular targets for SV40 Large T-antigen

J. Yewdell, D. Lane, J. Gannon, 1985, Proceedings of the Royal Society of London. Series B. Biological Sciences.

Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions.

D. Lane, C. Stephen, C W Stephen, 1995, Journal of molecular biology.

Directed evolution of p53 variants with altered DNA-binding specificities by in vitro compartmentalization.

D. Lane, F. Ghadessy, D. Coomber, 2007, Journal of molecular biology.

p53 Family Pathway in Cancer

D. Lane, J. Bourdon, 2007 .

The Dual Interactions of p53 with MDM2 and p300: Implications for the Design of MDM2 Inhibitors

D. Lane, C. Verma, S. Kannan, 2019, International journal of molecular sciences.

EDITORIAL. p53—INTEGRATING THE COMPLEXITY

Peter A. Hall, David W. Meek, David P. Lane, 1996 .

p53--integrating the complexity.

D. Lane, P. Hall, D. Meek, 1996, The Journal of pathology.

Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage

Gergana Popova, K. Larsson, A. Thompson, 2018, Nature Communications.

A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage

Gergana Popova, K. Larsson, A. Thompson, 2018, Nature Communications.

Modulation of p53 binding to MDM2: computational studies reveal important roles of Tyr100

Chandra S. Verma, Shubhra Ghosh Dastidar, David P. Lane, 2009, BMC Bioinformatics.

Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1

C. Smythe, R. Fåhraeus, D. Lane, 1997, Current Biology.

Why is F19Ap53 unable to bind MDM2? Simulations suggest crack propagation modulates binding

D. Lane, C. Verma, S. G. Dastidar, 2012, Cell cycle.

Chemical states of the N-terminal “lid” of MDM2 regulate p53 binding: Simulations reveal complexities of modulation

Chandra S Verma, Shubhra Ghosh Dastidar, David P Lane, 2011, Cell cycle.

Multiple peptide conformations give rise to similar binding affinities: molecular simulations of p53-MDM2.

Shubhra Ghosh Dastidar, David P. Lane, Chandra S. Verma, 2008, Journal of the American Chemical Society.

Cell type-specific responses of human cells to inhibition of replication licensing

D. Lane, S. Shreeram, A. Sparks, 2002, Oncogene.

Bortezomib Stabilizes and Activates p53 in Proliferative Compartments of both Normal and Tumor Tissues In Vivo.

D. Lane, N. Barker, F. Ghadessy, 2019, Cancer research.

Evidence for allosteric effects on p53 oligomerization induced by phosphorylation

M. Fojta, D. Lane, B. Vojtesek, 2018, Protein science : a publication of the Protein Society.

Ku Selectively Transfers between DNA Molecules with Homologous Ends*

D. Lane, T. Bliss, Tonya M. Bliss, 1997, The Journal of Biological Chemistry.

Modulation of p53β and p53γ expression by regulating the alternative splicing of TP53 gene modifies cellular response

D. Lane, J. Bourdon, K. Fernandes, 2014, Cell Death and Differentiation.

p53 isoforms Δ133p53 and p53β are endogenous regulators of replicative cellular senescence

Borivoj Vojtesek, Curtis C. Harris, Izumi Horikawa, 2009, Nature Cell Biology.

Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis.

D. Lane, P. Workman, P. Fischer, 2004, Molecular cancer therapeutics.

p53 tumour suppressor

David Lane, Carol Prives, A. Levine, 1998, Current Biology.

The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot.

D. Lane, M. Marty, T. Soussi, 1992, Cancer research.

Inhibiting p53 Acetylation Reduces Cancer Chemotoxicity.

Hui Chin Goh, D. Lane, L. Hwang, 2017, Cancer research.

Non-structural protein 1 of parvoviruses: homology to purine nucleotide using proteins and early proteins of papovaviruses.

D. Lane, I. Anton, 1986, Nucleic acids research.

Identification of a putative RNA helicase in E.coli.

D. Lane, J. Southgate, S. Picksley, 1990, Nucleic acids research.

Proliferating cell nuclear antigen immunolocalization in gastro-intestinal epithelia.

D. Lane, P. Hall, C. Sarraf, 1991, Digestion.

Differential scanning fluorimetry as secondary screening platform for small molecule inhibitors of Bcl-XL

D. Lane, C. Brown, K. Wan, 2009, Cell cycle.

High intracellular stability of the spidroin N‐terminal domain in spite of abundant amyloidogenic segments revealed by in‐cell hydrogen/deuterium exchange mass spectrometry

J. Johansson, H. Jörnvall, D. Lane, 2019, The FEBS journal.

Assessing the Efficacy of Mdm 2 / Mdm 4-Inhibiting Stapled Peptides Using Cellular Thermal Shift Assays Ban

P. Nordlund, D. Lane, C. Brown, 2017 .

Assessing the Efficacy of Mdm2/Mdm4-Inhibiting Stapled Peptides Using Cellular Thermal Shift Assays

P. Nordlund, D. Lane, C. Brown, 2015, Scientific Reports.

Substrate Specificity of Cyclins Determined by Electrostatics

Gek Huey Chua, A. Krishnan, D. Lane, 2007, Cell cycle.

Characterization of Hydration Properties in Structural Ensembles of Biomolecules

Chee-Keong Kwoh, Chandra S Verma, Mohan Pradhan, 2019, J. Chem. Inf. Model..

p53 expression in colorectal adenomas.

A. Harris, D. Lane, N. Mortensen, 1993, The American journal of pathology.

SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment

I. Ellis, A. Green, E. Rakha, 2019, British Journal of Cancer.

The Stapled Peptide PM2 Stabilizes p53 Levels and Radiosensitizes Wild-Type p53 Cancer Cells

D. Lane, C. Brown, D. Spiegelberg, 2019, Front. Oncol..

Cell Viability Assays , 2 , 3-Bis ( 2-Methoxy-4-Nitro-5-Sulfophenyl )-2 H-Tetrazolium

D. Lane, C. Brown, D. Spiegelberg, 2019 .

Optimization of tetrahydroindazoles as inhibitors of human dihydroorotate dehydrogenase and evaluation of their activity and in vitro metabolic stability.

Gergana Popova, D. Lane, Neeraj Garg, 2020, Journal of medicinal chemistry.

On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: A Brownian dynamics study

Chandra S Verma, Reidun Twarock, Leo S D Caves, 2013, Cell cycle.

Characterization of the Ligand Receptor Encounter Complex and Its Potential for in Silico Kinetics-Based Drug Development.

Chandra S Verma, Reidun Twarock, Leo S D Caves, 2012, Journal of chemical theory and computation.

Title Binding of translationally controlled tumour protein to theN-terminal domain of HDM 2 is inhibited by Nutlin-3

D. Lane, C. Verma, F. Ghadessy, 2017 .

Binding of Translationally Controlled Tumour Protein to the N-Terminal Domain of HDM2 Is Inhibited by Nutlin-3

D. Lane, C. Verma, F. Ghadessy, 2012, PloS one.

Mdm2 in evolution.

D. Lane, C. Verma, 2012, Genes & cancer.

p53 isoforms regulate astrocyte-mediated neuroprotection and neurodegeneration

C. Harris, Xin Lu, E. Major, 2016, Cell Death and Differentiation.

The role of TP53 in breast cancer development.

R. Eeles, J. Bartek, J. Bártková, 1993, Cancer surveys.

p 53 mutations in colorectal cancer ( immunohistokogy / polymerase chain reaction / chemical mismatch cleavage / adenocarcinoma )

Bodmer, A. Rowan, D. Lane, 2022 .

p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish.

Zhenhai Zhang, D. Lane, J. Bourdon, 2009, Genes & development.

p53 and DNA polymerase alpha compete for binding to SV40 T antigen.

D. Lane, J. Gannon, 1987, Nature.

Interactions between SV40 T antigen and DNA polymerase alpha.

D. Lane, J. Gannon, 1990, The New biologist.

Ubiquitin-independent degradation of p53 mediated by high-risk human papillomavirus protein E6

D. Lane, C. F. Cheok, S. Laín, 2007, Oncogene.

p53: updates on mechanisms, biology and therapy (II)

D. Lane, C. Verma, 2019, Journal of molecular cell biology.

Hexamethylene Bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF-κB activity: Implications for cancer therapy

D. Lane, E. Wong, A. Dey, 2008, Cell cycle.

Combining native and ‘omics’ mass spectrometry to identify endogenous ligands bound to membrane proteins

C. Robinson, D. Lane, G. McAlister, 2020, Nature Methods.

A Mass‐Spectrometry‐Based Approach to Distinguish Annular and Specific Lipid Binding to Membrane Proteins

Alissa M. Hummer, C. Robinson, D. Lane, 2019, Angewandte Chemie.

Detecting and quantifying p53 isoforms at mRNA level in cell lines and tissues.

D. Lane, J. Bourdon, K. Fernandes, 2013, Methods in molecular biology.

Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange.

D. Lane, M. Walkinshaw, D. Zheleva, 2003, Structure.

Highly potent p21(WAF1)-derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A.

D. Lane, D. Zheleva, P. Fischer, 2002, The journal of peptide research : official journal of the American Peptide Society.

Water-Bridge Mediates Recognition of mRNA Cap in eIF4E.

Mohan R. Pradhan, C. Kwoh, D. Lane, 2016, Structure.

Water-Bridge Mediates Re cognition of mRNA Cap in eIF 4 E Graphical

Mohan R. Pradhan, C. Kwoh, D. Lane, 2016 .

Rational Optimization of Conformational Effects Induced By Hydrocarbon Staples in Peptides and their Binding Interfaces

Rajamani Lakshminarayanan, Dilraj Lama, Roger W. Beuerman, 2013, Scientific Reports.

A spatiotemporal characterization of the effect of p53 phosphorylation on its interaction with MDM2

Adelene Y. L. Sim, D. Lane, L. Caves, 2015, Cell cycle.

On the origin of the stereoselective affinity of Nutlin-3 geometrical isomers for the MDM2 protein

D. Lane, L. Caves, C. Verma, 2013, Cell cycle.

Lipids Shape the Electron Acceptor-Binding Site of the Peripheral Membrane Protein Dihydroorotate Dehydrogenase

E. Marklund, Gergana Popova, D. Lane, 2018, Cell chemical biology.

An immune complex assay for SV40 T antigen.

D. Lane, L. Crawford, 1977, Biochemical and biophysical research communications.

Improved eIF4E Binding Peptides by Phage Display Guided Design: Plasticity of Interacting Surfaces Yield Collective Effects

D. Lane, C. Verma, C. Brown, 2012, PloS one.

Anti-c-Met antibodies recognising a temperature sensitive epitope, inhibit cell growth

D. Lane, B. Vojtesek, Jeffrey Hill, 2013, Oncotarget.

Mutant p53, EGF receptor and c-erbB-2 expression in human breast cancer.

A. Harris, D. Lane, M. Greenall, 1991, Oncogene.

p53-dependent growth arrest following calcium phosphate-mediated transfection of murine fibroblasts.

D. Lane, J. Renzing, 1995, Oncogene.

Xenopus p53 is biochemically similar to the human tumour suppressor protein p53 and is induced upon DNA damage in somatic cells.

D. Lane, L. Cox, C. Midgley, 1994, Oncogene.

APC EXPRESSION IN NORMAL HUMAN TISSUES

D. Lane, P. Hall, C. Midgley, 1997, The Journal of pathology.

Phase II study of liarozole in advanced non-small cell lung cancer.

A. Harris, K. O'Byrne, D. Lane, 1998, European journal of cancer.

Constitutive activation of WASp leads to abnormal cytotoxic cells with increased granzyme B and degranulation response to target cells

J. Orange, Minghui He, S. Snapper, 2021, JCI insight.

The Novel Anti-cMet Antibody seeMet 12 Potentiates Sorafenib Therapy and Radiotherapy in a Colorectal Cancer Model

D. Lane, B. Vojtesek, P. Micke, 2020, Frontiers in Oncology.

Use of simian virus 40 large T-beta-galactosidase fusion proteins in an immunochemical analysis of simian virus 40 large T antigen

D. Lane, S. Mole, 1985, Journal of virology.

Exploitation of dihydroorotate dehydrogenase (DHODH) and p53 activation as therapeutic targets: A case study in polypharmacology

Gergana Popova, D. Lane, C. Verma, 2020, The Journal of Biological Chemistry.

The effects of Antibody Engineering CH and CL in Trastuzumab and Pertuzumab recombinant models: Impact on antibody production and antigen-binding

D. Lane, J. Yeo, S. Gan, 2018, Scientific Reports.

conditional expression with the tet system strategy to achieve tightly controlled in vivo Targeted transgenesis at the HPRT locus: an efficient

Michael B. Mann, D. Lane, F. Jaisser, 2015 .

Avoiding drug resistance through extended drug target interfaces: a case for stapled peptides

D. Lane, C. Verma, F. Ghadessy, 2016, Oncotarget.

Author's response to reviews Title: MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism Authors:

D. Lane, C. Purdie, A. Munro, 2008 .

Crystallization of eIF4E complexed with eIF4GI peptide and glycerol reveals distinct structural differences around the cap-binding site

D. Lane, M. Walkinshaw, C. Verma, 2009, Cell cycle.

Liposome Click Membrane Permeability Assay for Identifying Permeable Peptides

R. Evers, Joe R. Cannon, D. Lane, 2021, Pharmaceutical Research.

Seeking synergy in p53 transcriptional activation for cancer therapy.

D. Lane, C. F. Cheok, 2012, Discovery medicine.

Guardian of Genome Editing.

D. Lane, T. Ho, 2018, The CRISPR journal.

bioPROTACs as versatile modulators of intracellular therapeutic targets including proliferating cell nuclear antigen (PCNA)

D. Lane, C. Brown, Shuhui Lim, 2020, Proceedings of the National Academy of Sciences.

Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation

T. Tan, B. Goh, D. Lane, 2020, Nature Communications.

The p53 inducing drug dosage may determine quiescence or senescence

D. Lane, C. Verma, Cheok Chit Fang, 2010, Aging.

Cancer: How cells choose to die

D. Lane, 2001, Nature.

Regulation of the cryptic sequence-specific DNA-binding function of p53 by protein kinases.

D. Lane, T. Hupp, 1994, Cold Spring Harbor symposia on quantitative biology.

The Quantification of Antibody Elements and Receptors subunit expression using qPCR: The Design of VH, VL, CH, CL, FcR subunits primers for a more holistic view of the immune system

A. Wipat, D. Lane, S. Gan, 2019, bioRxiv.

The quantification of antibody elements and receptors subunit expression using qPCR: The design of VH, VL, CH, CL, FcR subunits primers for a more holistic view of the immune system.

A. Wipat, D. Lane, S. Gan, 2019, Journal of immunological methods.

Epitope analysis of the murine p53 tumour suppressor protein.

D. Lane, B. Vojtesek, T. Hupp, 1996, Oncogene.

Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.

D. Lane, P. Fischer, Shudong Wang, 2004, Chemistry & biology.

The conformational change of a murine temperature-sensitive p53 protein is independent of a change in phosphorylation status.

D. Lane, S. Picksley, D. Meek, 1992, Oncogene.

Tumor-Targeted Delivery of the p53-Activating Peptide VIP116 with PEG-Stabilized Lipodisks

K. Edwards, D. Lane, C. Brown, 2020, Nanomaterials.

New insights into p53 based therapy.

D. Lane, C. F. Cheok, C. Brown, 2011, Discovery medicine.

bioPROTACs as versatile modulators of intracellular therapeutic targets: Application to proliferating cell nuclear antigen (PCNA)

D. Lane, C. Brown, Shuhui Lim, 2019, bioRxiv.

Anthony Dipple Carcinogenesis Award. p53 from pathway to therapy.

D. Lane, 2004, Carcinogenesis.

A rapid antibody assay system for screening hybridoma cultures.

E. Lane, D. Lane, 1981, Journal of immunological methods.

Cellular responses to stress

D. Lane, C. Wolf, C. Downes, 1999 .

Stabilizing the eIF4G1 α-helix increases its binding affinity with eIF4E: implications for peptidomimetic design strategies.

C. Brown, D. Lane, C. Verma, 2011, Journal of molecular biology.

Monitoring flux in signalling pathways through measurements of 4EBP1-mediated eIF4F complex assembly

D. Lane, C. Brown, Y. Frosi, 2019, BMC Biology.

Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols.

M. Fernö, Å. Borg, D. Lane, 1995 .

Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.

D. Lane, J. Gannon, R. Iggo, 1990, The EMBO journal.

Conformational ordering of intrinsically disordered peptides for targeting translation initiation.

D. Lane, C. Verma, Dilraj Lama, 2020, Biochimica et biophysica acta. General subjects.

Increased expression of mutant forms of p53 oncogene in primary lung cancer

A. Harris, J. Bartek, D. Lane, 1990, The Lancet.

Tumour suppressor genes and molecular chaperones.

D. Lane, T. Hupp, C. Midgley, 1993, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

Stress, specificity and the NEDD8 proteome

D. Lane, David P. Lane, 2012, Cell cycle.

New approaches to cancer therapies

R. Fåhraeus, D. Lane, E. Krausz, 1999, The Journal of pathology.

p 53 mutant breast cancer patients expressing p 53 γ have as good a prognosis as wild-type p 53 breast cancer patients

A. Thompson, D. Lane, C. Purdie, 2017 .

Haemangiopericytomas: the prognostic value of immunohistochemical staining with a monoclonal antibody to proliferating cell nuclear antigen (PCNA)

D. Lane, C. Fletcher, P. Hall, 1991, Histopathology.

Using the polymerase chain reaction to modify expression plasmids for epitope mapping.

D. Lane, R. Iggo, S. Mole, 1989, Nucleic acids research.

Role of the N-terminal lid in regulating the interaction of phosphorylated MDMX with p53

D. Lane, Y. S. Tan, C. Verma, 2017, Oncotarget.

Modulation of the p53-MDM2 Interaction by Phosphorylation of Thr18: A Computational Study

Deepak Srinivasan, D. Lane, C. Verma, 2007, Cell cycle.

How to lose tumor suppression

D. Lane, 2019, Science.

A generic scaffold for conversion of peptide ligands into homogenous biosensors.

David P Lane, D. Lane, F. Ghadessy, 2013, Biosensors & bioelectronics.

Theprognostic significance oftheaccumulation ofp53tumour-suppressor geneprotein ingastric adenocarcinoma

D. Lane, E. Newman, D. Hopwood, 1994 .

INTERRUPTION OF TYING PROTEINS MDM2 AND p53 AND RELATED THERAPEUTIC APPLICATIONS

David P. Lane, Steven M. Picksley, D. Lane, 1995 .

Forces mediating protein–protein interactions: a computational study of p53 “approaching” MDM2

Shubhra Ghosh Dastidar, Chandra Verma, David P. Lane, 2010 .

Monitoring flux in signalling pathways through measurements of 4EBP1-mediated eIF4F complex assembly

D. Lane, C. Brown, Y. Frosi, 2019, BMC Biology.

Macrocyclic α helical peptide therapeutic modality: A perspective of learnings and challenges.

A. Peier, D. Lane, J. Hochman, 2018, Bioorganic & medicinal chemistry.

Bortezomib Stabilizes and Activates p53 in Proliferative Compartments of both Normal and Tumor Tissues In Vivo.

D. Lane, N. Barker, F. Ghadessy, 2019, Cancer research.

Why is F19Ap53 unable to bind MDM2? Simulations suggest crack propagation modulates binding

D. Lane, C. Verma, S. G. Dastidar, 2012, Cell cycle.

Phosphatase WIP1 regulates adult neurogenesis and WNT signaling during aging.

D. Lane, Yunhua Zhu, O. Demidov, 2014, The Journal of clinical investigation.

Stapled peptides with improved potency and specificity that activate p53.

D. Lane, C. Verma, C. Brown, 2013, ACS chemical biology.

Mass Spectrometry Reveals the Direct Action of a Chemical Chaperone.

E. Marklund, J. Johansson, D. Lane, 2018, The journal of physical chemistry letters.

Structural insights reveal a recognition feature for tailoring hydrocarbon stapled-peptides against the eukaryotic translation initiation factor 4E protein† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c8sc03759k

D. Lane, C. Verma, Dilraj Lama, 2019, Chemical science.

Water-Bridge Mediates Recognition of mRNA Cap in eIF4E.

Mohan R. Pradhan, C. Kwoh, D. Lane, 2016, Structure.

Stapled peptide design: principles and roles of computation.

D. Lane, Y. S. Tan, C. Verma, 2016, Drug discovery today.

NanoClick: A High Throughput, Target-Agnostic Peptide Cell Permeability Assay.

A. Peier, D. Lane, J. Hermes, 2021, ACS chemical biology.

On the origin of the stereoselective affinity of Nutlin-3 geometrical isomers for the MDM2 protein

D. Lane, L. Caves, C. Verma, 2013, Cell cycle.

Supporting Information Macrocyclization of an all-D linear α-helical peptide imparts cellular permeability

Yuri, D. Lane, L. Rénia, 2020 .

Multiple peptide conformations give rise to similar binding affinities: molecular simulations of p53-MDM2.

D. Lane, C. Verma, S. G. Dastidar, 2008, Journal of the American Chemical Society.

Investigating peptide sequence variations for 'double-click' stapled p53 peptides.

D. Spring, D. Lane, G. McKenzie, 2014, Organic & biomolecular chemistry.

Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents.

D. Lane, R. Jackson, D. Zheleva, 2010, Chemistry & biology.

Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome

D. Lane, P. Neilsen, D. Callen, 2011, Oncotarget.

Detecting p53 isoforms at protein level.

D. Lane, J. Bourdon, K. Fernandes, 2013, Methods in molecular biology.

A highly sensitive fluorescent light-up probe for real-time detection of the endogenous protein target and its antagonism in live cells.

B. Liu, D. Lane, F. Ghadessy, 2015, Journal of materials chemistry. B.

Inhibition of NLRP3 inflammasome activation by cell-permeable stapled peptides

D. Lane, C. Verma, Arumay Pal, 2019, Scientific Reports.

The electrostatic surface of MDM2 modulates the specificity of its interaction with phosphorylated and unphosphorylated p53 peptides

Deepak Srinivasan, D. Lane, C. Verma, 2008, Cell cycle.

159 Stapled-peptides targeting the protein-binding interface of eukaryotic Translation Initiation Factor 4E (eIF4E) protein

D. Lane, C. Verma, Dilraj Lama, 2015, Journal of biomolecular structure & dynamics.